Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/4785
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMelo, Andreia Cristina de-
dc.contributor.authorAlves, Lísia Daltro Borges-
dc.contributor.authorFarinha, Thayana Alves-
dc.contributor.authorAraújo, Luiz Henrique de Lima-
dc.contributor.authorThiago, Leandro de Souza-
dc.contributor.authorDias, Fernando Luiz-
dc.contributor.authorAntunes, Héliton Spíndola-
dc.contributor.authorEisenberg, Ana Lucia Amaral-
dc.contributor.authorThuler, Luiz Claudio Santos-
dc.contributor.authorGoldemberg, Daniel Cohen-
dc.date.accessioned2021-12-15T13:04:14Z-
dc.date.available2021-12-15T13:04:14Z-
dc.date.issued2021-
dc.identifier.citationMELO, Andreia Cristina de et al. A systematic review of secretory carcinoma of the salivary gland: where are we? Oral and Maxillofacial Pathology, v. 132, n. 4, p. 143-152, oct. 2021.-
dc.identifier.issn2212-4403-
dc.identifier.urihttp://sr-vmlxaph03:8080/jspui/handle/123456789/4785-
dc.descriptionp. 143-152.: tab. p&b.-
dc.description.abstractThe aim of this systematic review was to describe the epidemiology, diagnostic criteria, differential diagnosis, treat ment, prognostic factors, and treatment outcomes of secretory carcinoma. Study Design. A comprehensive search of Lilacs, PubMed, Science Direct, and Web of Science databases was conducted to iden tify all case reports, letter to the editor, and histopathologic reclassifications regarding salivary gland secretory carcinoma pub lished in English, Spanish, French, and Portuguese. Results. The final analysis included 119 studies, which totaled 642 secretory carcinoma diagnoses, with 239 case reports and 403 diagnostic reclassifications, mostly in the United States. The age range was 5 to 87 years, and cases were predominantly in males (58.7%) and mostly affecting the parotid glands (73.7%). The disease usually presents as a slow-growing, painless mass. The main differential diagnosis is acinic cell carcinoma, and the tumor is usually treated with surgery. The prognosis is considered favor able, although there have been reports of local recurrences, distant metastases, and deaths. Conclusions. It is important that clinicians become aware of this salivary gland neoplasm and report clinical data, clinical course, management and long-term follow-up. There is an urgent need to conduct more clinical trials, especially on tropomyosin receptor kinase (TRK) inhibitors and other potential target therapy modalities.-
dc.publisherOral and Maxillofacial Pathologypt_BR
dc.subjectRevisão Sistemáticapt_BR
dc.subjectSystematic Reviewpt_BR
dc.subjectCarcinomapt_BR
dc.subjectCarcinomapt_BR
dc.subjectProteínas e Peptídeos Salivarespt_BR
dc.subjectSalivary Proteins and Peptidespt_BR
dc.titleA systematic review of secretory carcinoma of the salivary gland: where are we?pt_BR
dc.TypeArticlept_BR
Appears in Collections:Artigos de Periódicos da área de Ginecologia



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.